A phase II dose-ranging study of mirabegron in patients with overactive bladder

Christopher R. Chapple*, Vladimir Dvorak, Pjotr Radziszewski, Philip Van Kerrebroeck, Jean Jacques Wyndaele, Brigitte Bosman, Peter Boerrigter, Ted Drogendijk, Arwin Ridder, Ingrid Van der Putten-Slob, Osamu Yamaguchi

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1447-1458
JournalInternational Urogynecology Journal
Volume24
Issue number9
DOIs
Publication statusPublished - Sep 2013

Keywords

  • beta(3)-adrenoceptor agonist
  • Mirabegron
  • Overactive
  • Urinary bladder

Cite this